Japanese pharmaceutical firm Astellas has began its Phase III trial of gilteritinib (ASP2215) in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML).

Overall survival (OS) is the main focus of the Phase III trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Discovered through a research collaboration between Astellas and Kotobuki Pharmaceutical, gilteritinib is a receptor tyrosine kinase inhibitor of FLT3 and AXL, which are involved in cancer cell growth.

Astellas has exclusive global rights to develop, manufacture and potentially commercialise gilteritinib, which has shown inhibitory activity against internal tandem duplication (ITD) and tyrosine kinase domain (TKD), two common FLT3 mutations seen in up to a third of patients with AML.

"Overall survival (OS) is the main focus of the Phase III trial."

Phase III is an open-label, multicentre trial of gilteritinib in around 369 patients with FLT3-activating mutations in bone marrow or whole blood. It follows a Phase I/II trial evaluating the effects of single daily doses from 20mg to 450mg.

See Also:

In the new trial, patients will be randomised in a 2:1 ratio to receive either 120mg of gilteritinib or salvage chemotherapy consisting of LoDAC, azacitidine, MEC (mitoxantrone, etoposide, and intermediate-dose cytarabine), or FLAG-IDA (fludarabine, cytarabine, and granulocyte colony-stimulating factor with idarubicin).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A parallel multi-dose expansion group was started based on the efficacy seen in the dose escalation phase.

Preliminary data from the Phase I/II trial showed a 57.5% overall response rate and a 47.2% composite complete response (CR) rate. The results were based on 106 patients with FLT3 mutations, who received doses at 80mg and over.

Median duration of response was 18 weeks across all doses, while median OS was about 27 weeks at 80mg and above in FLT3 mutation-positive patients.

The maximum tolerated dose was determined to be 300mg after two patients reached dose-limiting toxicity at 450mg.

Earlier this month, the Japanese Ministry of Health, Labour and Welfare (MHLW) selected gilteritinib as one of the first products designated for Sakigake, which can shorten the review period in prioritised consultation, substantial pre-application consultation and prioritised review.